BRIDGEWATER, N.J., Nov. 19, 2012 /PRNewswire/ -- Sanofi today announced that, through its Sanofi Foundation for North America, it is contributing $500,000 in cash, for disaster relief efforts to help assist the victims of Hurricane Sandy in New Jersey. The funds will be distributed to the Hurricane Sandy New Jersey Relief Fund, the Community Food Bank of New Jersey and the Children's Health Fund for both immediate and long-term needs. The storm left millions in the mid-Atlantic and New England without power, food and other necessities and may result in $50 billion in economic losses.
"This storm has been a catastrophe that has touched us all. With our U.S. headquarters in Bridgewater, New Jersey, where much of the damage occurred, we have seen, first-hand, the devastating impact of Hurricane Sandy on our employees, friends and neighbors. Our heart goes out to the victims of the storm," said Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "We are committed to helping those impacted by the storm and hope that our assistance will support the incredible relief efforts that are underway in the hardest hit areas at the point of need."
A special Hurricane Sandy Disaster Relief program sponsored by the Sanofi Foundation for North America will match dollar-for-dollar all donations between $25 and $2,500 made by U.S. employees directly to the American Red Cross. Sanofi US will continue its year-round matching gifts program through AmeriGives, which will match donations to 501(c)(3) organizations that meet program criteria.
Additional support from Sanofi to Sandy's disaster relief efforts includes the donation of medications, over-the-counter products, and vaccines through its partnership with Direct Relief International and AmeriCares.
Sanofi's employees have offered unwavering assistance to peers and their communities assisting through direct, hands-on volunteer efforts for care-package assembly, time and talents offerings, and other donations.
About the Sanofi Foundation for North America
The Sanofi Foundation for North America makes it possible to provide free prescription drugs to patients who do not have insurance coverage and who meet program eligibility requirements. Product is donated to the Foundation by the company for this purpose. The Foundation also provides monetary support and partners with charities and 501(c)3 organizations and other entities that are strategically aligned with mission particularly access to health care.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects","anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.